Review Article
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
Table 1
Characteristics of the analysed trials.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PFS: Progression free survival; OS: Overall survival. III lines: 36% placebo; 34% apatinib III lines: 62% placebo; 63% TAS-102 III lines: 82% placebo; 80% nivolumab |